Anticardiolipin Antibodies (ACL), Factor V Leiden (FVL) and G20210A Prothrombin Mutation (G20210AII) Do Not Predispose Renal Transplant Recipients to Thrombotic Complications or Graft Loss
Abstract number: P1131
Rocha1 LKA, Castillo1 V, Pestana2 JOM, Vaz2 MLS, Ozaki2 KS, Andrade3 LEC, Amaral3 RQ, Nogutti1 MAE, Lourenço1 DM
11Division of Hematolog, Universidade Federal de São Paulo, São Paulo, Brazil 11Division of Hematolog, Universidade Federal de São Paulo, São Paulo, Brazil 22Division of Nephrology, Universidade Federal de São Paulo, São Paulo, Brazil 33Division of Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil
The aim of the study was to investigate the prevalence of thrombophilia in renal allograft recipients and its possible relation to graft loss or thrombotic complications.
FVL, G20210AII and ACL were investigated in 388 patients who had undergone renal transplantation from May 2001 to July 2002. Genotype study was also performed in 134 normal subjects. ACL was measured by ELISA and was considered positive if GPL > 20 U or MPL > 12 U. FVL or G20210AII were detected in 19 patients (6 FVL and 13 G20210AII) and in 4 controls (3 FVL and 1 G20210AII), OR = 1.7 (95%CI 0.65.0), P= 0.47. Forty patients had complications: 28 lost the graft and 12 had thrombosis (5 graft thrombosis and 7 at other sites). FVL was detected in 1 patient with complication (2.5%) and in 5 patients without complication (1.4%). G20210AII was observed in 13 patients without complication (3.7%) and in no patient with complication. Positive ACL was detected in 6 patients with complication (15.0%) and in 82 patients without complication (23.6%). Overall, the presence of thrombophilia was observed in 7 patients with complication (17.5%) and in 100 subjects without complication (28.7%), OR = 0.5 (95%CI 0.21.2), P= 0.19. ACL antibodies are highly prevalent among Brazilian renal transplant recipients, whereas FVL and G20210AII are not. The presence of these thrombophilic factors did not predispose renal allograft recipients to venous thromboembolic complications or graft loss.
To cite this abstract use the following format:
Journal of Thrombosis and Haemostasis 2005; Volume 3, Supplement 1: abstract number
|Session name:||XXIst ISTH Congress|
|Subject:||Posters Session Tuesday|
|Back to top|